Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report)’s stock price traded down 0.7% during mid-day trading on Friday . The company traded as low as $14.16 and last traded at $14.95. 1,494,645 shares traded hands during mid-day trading, an increase of 207% from the average daily volume of 486,688 shares. The stock had previously closed at $15.05.
Eliem Therapeutics Price Performance
The company has a fifty day simple moving average of $14.21 and a two-hundred day simple moving average of $11.04. The company has a market capitalization of $444.79 million, a P/E ratio of -28.21 and a beta of -0.39.
Eliem Therapeutics Company Profile
Eliem Therapeutics, Inc is a clinical?stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small?molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor?specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.
The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.
Further Reading
- Five stocks we like better than Eliem Therapeutics
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
